Trials / Completed
CompletedNCT03482232
Consequences of Doing What Should Not be Done in Primary Care
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 750,000 (actual)
- Sponsor
- Universidad Miguel Hernandez de Elche · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Retrospective observational study in a random selection of 5% of digital records active between 2014 and 2017 to quantify the frequency of Do not do primary care recommendations, calculating the over-cost related to them and study reviewing a random selection of cases previously identified to determine whether patient suffered adverse events and their over-cost.
Detailed description
Basement: Overuse subjected patients to unnecessary risk without promoting a sufficient clinical benefit and over-cost. The Less is More Medicine movement has led to the identification of Do not do in different specialties, also in primary care. Objective: To analyze the impact of errors (overuse rates based in Do not do recommendations) in clinical practice. Method: Retrospective observational study in a random selection of 5% of digital records active between 2014 and 2017 to quantify the frequency of Do not do primary care recommendations, calculating the over-cost related to them. Retrospective study reviewing a random selection of cases previously identified to determine whether patient suffered adverse events and their over-cost. Setting. Primary care in Andalucía, Aragón, Castilla La Mancha, Comunidad Valenciana, Madrid, Murcia, Navarra y País Vasco, eight autonomous communities in Spain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Benzodiazepines | Benzodiazepines for insomnia, agitation or delirium in people older than 65 |
| DRUG | Non-steroidal anti-inflammatory drugs | Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis |
| DRUG | paracetamol | paracetamol 1g for more than 3 days |
| DRUG | Antimicrobial agent | antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy |
| DRUG | Lipid-lowering drug | Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events |
| DIAGNOSTIC_TEST | Prostate cancer | Screening for prostate cancer in asymptomatic patients |
| RADIATION | Lumbago | image tests in non-specific lumbago |
| DRUG | Antimicrobial agent | antibiotics for pharyngitis (infants) |
| DRUG | Mucolytic | mucolytics, antitussives or antibiotics for upper respiratory infections (infants) |
| DRUG | Ibuprofen and paracetamol | treatment with ibuprofen and paracetamol (infants) |
Timeline
- Start date
- 2018-10-14
- Primary completion
- 2019-12-05
- Completion
- 2020-02-10
- First posted
- 2018-03-29
- Last updated
- 2020-04-03
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT03482232. Inclusion in this directory is not an endorsement.